NCT05478486 2026-02-04
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
Phase 1 Completed
Clinical Trials
8 trialsNCT04278859 2025-06-19
Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT03172819 2022-09-28
Special Combination of OBP-301 and Pembrolizumab
National Cancer Center Hospital East
Phase 1 Completed
NCT03163732 2022-05-09
PROFILER 02
Centre Leon Berard
Phase NA Completed
NCT00509613 2009-09-18
Phase 1 Study With Sorafenib and Sirolimus
Radboud University Medical Center
Phase 1 Completed